Rabson-Mendenhall syndrome (RMS) is a rare genetic disorder characterized by growth retardation, dysmorphisms, lack of subcutaneous fat, acanthosis nigricans, enlarged genitalia, hirsutism, dysplastic dentition, coarse facial features, abnormal glucose homeostasis, hyperinsulinemia and pineal hyperplasia. Herein, we describe a 13-year-old girl with physical features of RMS who presented to us on account of acanthosis nigricans.

Verrucae (synonym: warts) are one of the most common viral infections of humans in which the most frequently used modalities of treatment involve destruction of the affected area, which does not prevent recurrences and often results in scarring. In the present study oral zinc sulphate, an immunomodulator was evaluated as a treatment modality for warts. A placebo-controlled, single-blinded study was conducted on one hundred OPD patients with various types of verrucae. Fifty patients were put on oral zinc sulphate at dose of 5mg/kg for six weeks, while an equal number of patients received placebo for the same duration. In the patients who received oral zinc sulphate, 60.97% showed complete response at the end of six weeks in comparison to 6.45% partial response in the placebo group. The resolution of the lesions occurred with restoration of normal epidermal texture with transient alteration in pigmentation.

No abstract

Introduction: Chronic urticaria is a disabling disease which may be refractory to standard therapies. Leukotriene receptor antagonists like montelukast have been tried in allergic diseases like asthma and find mention as a therapeutic option in chronic urticaria. Purposes: A randomized single-blinded non-placebo controlled study to evaluate the role of montelukast, in addition to the adjunctive role of non-sedating antihistamine levocetirizine (H1), was conducted in patients with chronic urticaria. Methods: Thirty-five patients with chronic urticaria were enrolled. Medication was given for a period of twelve weeks. Montelukast 10mg/ day in an adult and 5mg in the age group 6-13 years, 4mg 2-6 years and levocetirizine 5mg once a day was added, if patient had new weals while on therapy. The improvement was monitored by estimating the episodes of wheals and pruritus in any two weeks period. Results: Twenty-two patients showed a good response with occasional wheals at the end of 2 weeks and no weals at the end of 12 weeks. These included all 8 patients on non-steroidal anti-inflammatory drugs (NSAIDS). Four of these patients relapsed on discontinuation of therapy. Conclusions: Montelukast is effective in chronic refractory urticaria especially in patients on non-steroidal anti-inflammatory drugs with occasional add-on use of a non-sedating anti-histamine.